Genomics and Pharmacogenomics in Anticancer Drug Development and Clinical Response

✍ Scribed by Natalie Stickle MSc, Neil Winegarden MSc (auth.), Federico Innocenti (eds.)

• Publisher: Humana Press
• Year: 2009
• Tongue: English
• Leaves: 379
• Series: Cancer Drug Discovery and Development™
• Edition: 1
• Category: Library

✦ Synopsis

The availability of new molecular approaches to the selection of drug therapy is an emerging need, as the traditional approach based on the evaluation of patient and tumor characteristics is clearly far from optimal. Many, and in most cases the majority of treated patients do not have significant benefits from the treatment while they often experience moderate to severe toxicities. In "Pharmacogenomics, Anticancer Drug Discovery, and Response," edited by Federico Innocenti, readers will find a series of chapters addressing the role of genomic information in cancer therapy and in drug development representing a unique source, as it describes experimental approaches, statistical strategies, and clinical examples of the application of genomic medicine in oncology. This book provides the most comprehensive body of knowledge on the role of genetic and genomic variation in the individualization of drug therapies in cancer patients.

✦ Table of Contents

Front Matter....Pages i-xiv
Front Matter....Pages 1-1
Toward the Realization of the Promise of Microarrays in Oncology....Pages 3-18
Cell-Based Models to Identify Genetic Variants Contributing to Anticancer Drug Response....Pages 19-31
Proteomic Analysis in Cancer Patients....Pages 33-45
MicroRNAs and Discovery of New Targets....Pages 47-56
Pharmacogenomics of the National Cancer Institute’s 60-Tumor Cell Panel....Pages 57-74
Use of Single-Nucleotide Polymorphism Array for Tumor Aberrations in Gene Copy Numbers....Pages 75-88
Front Matter....Pages 90-90
Concordance Between Tumor and Germline DNA....Pages 91-101
Epidermal Growth Factor Receptor Mutations and Sensitivity to Selective Kinase Inhibitors in Human Lung Cancer....Pages 103-126
BCR-ABL Mutations and Imatinib Resistance in Chronic Myeloid Leukemia Patients....Pages 127-150
Role of Thymidylate Synthase Gene Variations in Colorectal Cancer Patients....Pages 151-172
Thiopurines in the Treatment of Childhood Acute Lymphoblastic Leukemia and Genetic Variants of the Thiopurine S-Methyltransferase Gene....Pages 173-201
Impact of Polymorphisms on the Clinical Outcomes of Monoclonal Antibody Therapy Against Hematologic Malignancies....Pages 203-229
DNA Repair and Mitotic Checkpoint Genes as Potential Predictors of Chemotherapy Response in Non-Small-Cell Lung Cancer....Pages 231-247
Dihydropyrimidine Dehydrogenase (Dpyd) Gene Polymorphism: Portrait of a Serial Killer....Pages 249-265
Impact of UDP-Glucuronosyltransferase 1A Haplotypes on Irinotecan Treatment....Pages 267-286
Microarray Profiling in Breast Cancer Patients....Pages 287-298
Role of the Folate-Pathway and the Thymidylate Synthase Genes in Pediatric Acute Lymphoblastic Leukemia Treatment Response....Pages 299-310
Front Matter....Pages 311-311
Pharmacogenomics in Drug Development: A Pharmaceutical Industry Perspective....Pages 313-325
Identification of Pharmacogenomic Biomarker Classifiers in Cancer Drug Development....Pages 327-338
Toxicogenomics Application to Oncology Drug Development....Pages 339-351
Front Matter....Pages 311-311
Strategies to Identify Pharmacogenomic Biomarkers: Candidate Gene, Pathway-Based, and Genome-Wide Approaches....Pages 353-370
Back Matter....Pages 371-377

✦ Subjects

Cancer Research; Pharmacology/Toxicology; Human Genetics